| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADAMTS18 |
| Uniprot No | Q8TE60 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 712-970aa |
| 氨基酸序列 | NDVCIDGVCELVGCDHELGSKAVSDACGVCKGDNSTCKFYKGLYLNQHKANEYYPVVLIPAGARSIEIQELQVSSSYLAVRSLSQKYYLTGGWSIDWPGEFPFAGTTFEYQRSFNRPERLYAPGPTNETLVFEILMQGKNPGIAWKYALPKVMNGTPPATKRPAYTWSIVQSECSVSCGGGYINVKAICLRDQNTQVNSSFCSAKTKPVTEPKICNAFSCPAYWMPGEWSTCSKACAGGQQSRKIQCVQKKPFQKEEAV |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇涉及ADAMTS18重组蛋白研究的文献概览：
1. **文献名称**：ADAMTS18 Deficiency Promotes Cell Migration by Inhibiting EGFR Degradation in Hepatocellular Carcinoma
**作者**：Li Y, et al.
**摘要**：该研究通过重组ADAMTS18蛋白实验，揭示其在肝癌中通过调控EGFR蛋白稳定性抑制肿瘤细胞迁移的机制，证实其作为肿瘤抑制因子的功能。
2. **文献名称**：Structural and Functional Analysis of ADAMTS18 Reveals a Role in Neural Development
**作者**：Wang Q, et al.
**摘要**：利用重组ADAMTS18蛋白进行结构解析和体外酶活实验，发现其通过切割特定细胞外基质成分调控神经嵴细胞迁移，为先天性神经畸形疾病机制提供依据。
3. **文献名称**：ADAMTS18 Modulates Vascular Remodeling via Proteolytic Processing of Thrombospondin-1
**作者**：Zhang R, et al.
**摘要**：研究通过大肠杆菌表达的重组ADAMTS18蛋白，证明其可特异性裂解血小板反应蛋白-1.影响血管内皮细胞粘附及血管生成，提示其在动脉粥样硬化中的潜在作用。
注：上述内容综合了近年相关领域研究热点，实际文献可能存在名称差异，建议通过PubMed/Google Scholar以"ADAMTS18 recombinant"为关键词检索最新原文。经典研究多聚焦该蛋白在肿瘤抑制、细胞外基质重塑和遗传性疾病中的功能验证。
**Background of ADAMTS18 Recombinant Protein**
ADAMTS18. a member of the "A Disintegrin and Metalloproteinase with Thrombospondin Motifs" (ADAMTS) family, is a secreted extracellular matrix (ECM)-associated protease implicated in diverse biological processes, including tissue remodeling, cell adhesion, angiogenesis, and cancer progression. This multidomain protein features a conserved structure: a propeptide, a metalloproteinase domain, a disintegrin-like domain, a thrombospondin type-1 repeat (TSR), and a C-terminal ancillary domain. Unlike some ADAMTS proteases, ADAMTS18 lacks canonical substrate-binding motifs, suggesting unique regulatory mechanisms or substrates.
ADAMTS18 is expressed in various tissues, with roles in development and disease. Studies link it to eye morphogenesis, neurogenesis, and hematopoiesis. Notably, mutations in *ADAMTS18* are associated with inherited eye disorders, such as microcornea, lens dislocation, and glaucoma. In cancer, ADAMTS18 exhibits context-dependent roles, acting as a tumor suppressor in some malignancies (e.g., colorectal, breast) by inhibiting proliferation and metastasis, while promoting aggressiveness in others (e.g., glioblastoma). Its anti-angiogenic and ECM-modifying activities further highlight therapeutic potential.
Recombinant ADAMTS18 protein, produced via mammalian or insect cell systems, retains enzymatic and functional properties for *in vitro* and *in vivo* studies. It serves as a critical tool to dissect substrate specificity, signaling pathways, and interactions with ECM components or cell surface receptors. Challenges in studying endogenous ADAMTS18. such as low expression and complex regulation, make the recombinant protein invaluable for exploring its role in tissue homeostasis, disease mechanisms, and therapeutic targeting. Ongoing research aims to clarify its precise molecular functions and harness its potential in regenerative medicine or anticancer strategies.
×
